Cristal Therapeutics is a clinical stage pharmaceutical company.
Our mission is to create the next generation of targeted nanomedicines for improving the treatment of cancer and other diseases.
Our product candidates are centred on our proprietary polymeric nanoparticle construct called CriPec®. They are rationally designed to target specific tissue, cells and intracellular components, and to have a defined duration at disease sites.
Cristal Therapeutics is led by a management team of entrepreneurial life science executives and supported by an industry-experienced Supervisory Board and internationally renowned Scientific Board.
Watch Informa interview with our CEO/CMO, Dr Axel Mescheder at BIOEurope 2018
Location
The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.
Investment
Cristal Therapeutics is a private company that has raised over €30M in equity investments and grant awards to date.
History
Cristal Therapeutics was founded by Cristianne Rijcken, PhD, and Joost Holthuis, PhD, in 2011 as a spin-off of the Department of Pharmaceutical Sciences of the Utrecht University, The Netherlands.
IP Position
Cristal Therapeutics has an extensive patent estate that includes seven patent families covering its CriPec® platform and related products.
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 784127.